This guidance is for all patients with NICE NG12 symptoms of possible colorectal cancer excluding those with an anal or rectal mass/ulceration who should be referred on a lower gastrointestinal (LGI) Urgent Suspected Cancer (USC) pathway immediately.

This guidance should be used in place of existing NICE DG56/NICE NG12 guidance for the use of the faecal immunochemical test for haemoglobin (FIT) in the lower GI urgent suspected  cancer pathway. This guidance suggests a faecal haemoglobin (f-Hb) of≥10µg haemoglobin /gram faeces (µg/g) measured with a faecal immunochemical test (FIT) should be replaced with a COLOFIT ≥1% for referral to the Lower GI Urgent Suspected Cancer pathway. This threshold will be reviewed over time and may increase in future.

ACPGBI Consensus statement to support implementation can be read in full here, along with more information about the validation, implementation, target populations and referral pathways.